Purdue Pharma prepares for bankruptcy

Purdue Pharma, the maker of popular opioid OxyContin, is preparing to file for bankruptcy before the end of September if the company doesn’t reach a settlement over thousands of lawsuits against the company for its role in the opioid abuse epidemic, Reuters reported, citing people familiar with the matter.

The news comes just after it was reported a settlement with Purdue Pharma was fetching between $10 billion and $12 billion. The settlement would close the thousands of lawsuits against the pharma company and also extradite the Sackler family as the owners.

Purdue Pharma has become the face of blame for many of the thousands of opioid overdose deaths in the U.S., and OxyContin has handed the Sacklers billions in profits. The company and the Sacklers have denied accusations that their actions and marketing tactics helped fuel the U.S. opioid crisis. In 2018, 68,000 people died from opioid overdose.

The company is prepared to file Chapter 11 bankruptcy “at a moment’s notice,” Reuters reported. A federal judge on the settlement case wants 35 state attorneys general to sign off on the deal, though some states have reportedly opposed it.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.